Literature DB >> 19371324

Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues.

Nuggehally R Srinivas.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19371324      PMCID： PMC2679114          DOI： 10.1111/j.1365-2125.2009.03374.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  23 in total

1.  Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.

Authors:  Gideon A Paul; J Simon R Gibbs; Alan R Boobis; Allifia Abbas; Martin R Wilkins
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

2.  Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man.

Authors:  D K Walker; M J Ackland; G C James; G J Muirhead; D J Rance; P Wastall; P A Wright
Journal:  Xenobiotica       Date:  1999-03       Impact factor: 1.908

3.  In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions.

Authors:  J S Warrington; R I Shader; L L von Moltke; D J Greenblatt
Journal:  Drug Metab Dispos       Date:  2000-04       Impact factor: 3.922

4.  Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.

Authors:  Barbara J Ring; Beverley E Patterson; Malcolm I Mitchell; Mark Vandenbranden; Jennifer Gillespie; Alun W Bedding; Hayley Jewell; Christopher D Payne; S Thomas Forgue; James Eckstein; Steven A Wrighton; Diane L Phillips
Journal:  Clin Pharmacol Ther       Date:  2005-01       Impact factor: 6.875

Review 5.  Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.

Authors:  Jasper Dingemanse; Paul L M van Giersbergen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil.

Authors:  Gary J Muirhead; David J Rance; Donald K Walker; Philip Wastall
Journal:  Br J Clin Pharmacol       Date:  2002       Impact factor: 4.335

7.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Authors:  Gerald Simonneau; Robyn J Barst; Nazzareno Galie; Robert Naeije; Stuart Rich; Robert C Bourge; Anne Keogh; Ronald Oudiz; Adaani Frost; Shelmer D Blackburn; James W Crow; Lewis J Rubin
Journal:  Am J Respir Crit Care Med       Date:  2002-03-15       Impact factor: 21.405

Review 8.  The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.

Authors:  Manish Gupta; Andreas Kovar; Bernd Meibohm
Journal:  J Clin Pharmacol       Date:  2005-09       Impact factor: 3.126

9.  Tadalafil pharmacokinetics in healthy subjects.

Authors:  S Thomas Forgue; Beverley E Patterson; Alun W Bedding; Christopher D Payne; Diane L Phillips; Rebecca E Wrishko; Malcolm I Mitchell
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

10.  Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.

Authors:  M R Wilkins; J Wharton; F Grimminger; H A Ghofrani
Journal:  Eur Respir J       Date:  2008-07       Impact factor: 16.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.